Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia

The majority of patients with chronic myeloid leukemia are successfully managed with life-long treatment with tyrosine kinase inhibitors. In patients in chronic phase, other malignancies are among the most common causes of death, raising concerns on the relationship between these deaths and the off-...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Haematologica
Autors principals: Gugliotta, Gabriele, Castagnetti, Fausto, Breccia, Massimo, Albano, Francesco, Iurlo, Alessandra, Intermesoli, Tamara, Abruzzese, Elisabetta, Levato, Luciano, D’Adda, Mariella, Pregno, Patrizia, Cavazzini, Francesco, Stagno, Fabio, Martino, Bruno, La Barba, Gaetano, Sorà, Federica, Tiribelli, Mario, Bigazzi, Catia, Binotto, Gianni, Bonifacio, Massimiliano, Caracciolo, Clementina, Soverini, Simona, Foà, Robin, Cavo, Michele, Martinelli, Giovanni, Pane, Fabrizio, Saglio, Giuseppe, Baccarani, Michele, Rosti, Gianantonio
Format: Artigo
Idioma:Inglês
Publicat: Ferrata Storti Foundation 2017
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5685244/
https://ncbi.nlm.nih.gov/pubmed/28572163
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2017.169532
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars